Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 10/20 | 0.46 |
| ▸ | PPARA | Q07869 | 5/20 | 0.43 |
| ▸ | TRPM2 | O94759 | 1/20 | 0.42 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.40 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.40 |
| ▸ | SLC34A1 | Q06495 | 1/20 | 0.39 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.38 |
| ▸ | PPARG | P37231 | 1/20 | 0.37 |
| ▸ | FPR2 | P25090 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5023737 | 0.92 | PPARD (0.45) | PPARDPPARATRPM2MCL1MAOB | |
| SCHEMBL5023397 | 0.91 | PPARD (0.56) | PPARDPPARAMCL1PPARG | |
| SCHEMBL5016822 | 0.89 | MCL1 (0.46) | MCL1SLC34A1 | |
| SCHEMBL5016769 | 0.85 | PPARD (0.44) | PPARDPPARATRPM2MCL1MAOB | |
| SCHEMBL5025641 | 0.82 | PPARD (0.55) | PPARDPPARAMCL1GRIN1GRIN2B | |
| SCHEMBL6017213 | 0.80 | PPARD (0.47) | PPARDPPARAMCL1MAOBGRIN1 | |
| SCHEMBL5023329 | 0.80 | MCL1 (0.44) | PPARDPPARATRPM2MCL1GRIN1 | |
| SCHEMBL5023827 | 0.79 | MCL1 (0.48) | PPARDPPARAMCL1PPARG | |
| SCHEMBL6029063 | 0.79 | PPARD (0.47) | PPARDPPARAMCL1MAOBGRIN1 | |
| SCHEMBL5023384 | 0.79 | PPARD (0.42) | PPARDPPARATRPM2MCL1MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1725546-B1 | PYRAZOLYL INDOLYL DERIVATIVES AS PPAR ACTIVATORS | HOFFMANN LA ROCHE (CH) | 2008-10-08 | — | — | EP | disclosed |
| US-7265149-B2 | Indolyl derivatives | HOFFMANN-LA ROCHE INC. (US) | 2007-09-04 | — | — | US | disclosed |
| US-20050203160-A1 | Indolyl derivatives | HOFFMANN-LA ROCHE INC. | 2005-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050203160-A1 | Indolyl derivatives | PPARD, PPARA, PPARG | PPARD 1/4885PPARA 2/4885TRPM2 2519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.